• The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.

  • May 29 2024
  • Duración: 51 m
  • Podcast

The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • What's preventing insurers from covering the specialized care of patients with nano-rare mutations, thereby expanding access to available treatment options? Is it the population size, cost, or perceived risk? Given that the initial discovery of nano-rare mutations is relatively recent, paving the way for this population requires a nuanced approach to overcome various obstacles. Alan Lotvin, M.D., CEO and co-founder of Sequel Med Tech, and former president of CVS Caremark, conceptualizes these hurdles.

    Más Menos
activate_WEBCRO358_DT_T2
Enfermedades Físicas Hygiene & Healthy Living Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles